Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche to present Avastin, MabThera data at ASCO

Roche to present Avastin, MabThera data at ASCO

24th May 2010

Roche has announced plans to highlight new clinical trial data for its Avastin and MabThera treatments at a forthcoming medical conference.

Phase III study results for the two treatments will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO), highlighting Avastin’s efficacy as a therapy for ovarian and colorectal cancer.

The data will also illustrate the potential effectiveness of maintenance use of MabThera as a treatment for incurable follicular lymphoma.

These results will be showcased as part of a wider presentation of Roche’s oncology portfolio at the event, with around 400 abstracts covering 30 cancer types set to be featured at ASCO.

Pascal Soriot, chief operating officer of Roche’s pharmaceuticals division, said: “Our targeted medicines have helped millions of people with cancer and we continue to learn more about who may benefit the most and how best to use our medicines.”

Earlier this month, Roche announced that it is to support a new international charity scheme which is designed to provide improved cancer care education and skills training in sub-Saharan Africa.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.